Pharmaceutical company Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals, announced on Saturday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Imuldosa (DMB-3115), a biosimilar to Stelara (ustekinumab), marketed by Janssen Biotech, a Johnson & Johnson subsidiary.

Ustekinumab is a monoclonal antibody targeting cytokines involved in inflammatory and immune responses.

The CHMP recommendation bolsters Accord Healthcare's position in the autoimmune market, where it already has several specialty brands. This development aligns with Accord's strategy to expand its specialty portfolio. The company has 10 additional biosimilars in development, reinforcing its commitment to improving patient access to value-based medicines.